Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
105.72
+4.72 (4.67%)
At close: Jul 21, 2026, 4:00 PM EDT
105.50
-0.22 (-0.21%)
After-hours: Jul 21, 2026, 4:38 PM EDT
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Dianthus Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $128.58. The average 1-year stock price forecast is 21.62% higher than the current stock price, while the lowest is $105 (-0.68%) and the highest is $200 (+89.18%).
Price Target: $128.58 (+21.62%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Dianthus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 15 | 16 | 15 | 15 | 15 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 16 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $130 | Buy | Reiterates | $130 | +22.97% | Jul 1, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $135 | Buy | Reiterates | $135 | +27.70% | Jun 17, 2026 |
| Jefferies | Jefferies | Buy Maintains $132 | Buy | Maintains | $132 | +24.86% | Jun 15, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 15, 2026 |
| Wedbush | Wedbush | Buy Maintains $105 | Buy | Maintains | $105 | -0.68% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
1.21M
from 2.04M
Decreased by -40.59%
Revenue Next Year
1.59M
from 1.21M
Increased by 31.06%
EPS This Year
-3.93
from -4.20
EPS Next Year
-4.65
from -3.93
EPS and Forward PE are based on non-GAAP adjusted numbers.